Longevity Segment Investability Tracker (2026)
In our longevity market deck, you will find everything you need to understand the market
Longevity Segment Investability Tracker
This table tracks 20 investability signals across eight longevity market segments, with each cell populated using publicly verifiable evidence from April 2024 to April 2026. Columns represent market segments ordered from most investable (left) to least investable (right).
The first column lists progressively deeper questions, from raw capital inflow to ecosystem formation, clinical validation, and strategic endorsement. Five composite scores at the bottom rate each segment as High, Medium, or Low. If you want to dig deeper into this market, you can check out our longevity market report.
| Question | Age-Related Disease Drugs | Drug Discovery Platforms | Cellular Reprogramming | Preventive Health | Biomarkers | Senolytics | Longevity Clinics | Consumer Products |
|---|---|---|---|---|---|---|---|---|
| Capital raised in the last 12 months? | ~$267M | ~$167M | ~$1,262M | ~$280M | ~$313M | ~$65M | ~$18M | ~$15M |
| Capital raised in the last 24 months? | ~$835M | ~$255M | ~$1,277M | ~$542M | ~$390M | ~$120M | ~$68M | ~$91M |
| Number of financings in the last 24 months? | 11 | 5 | 6 | 5 | 5 | 4 | 3 | 3 |
| Number of $50M+ financings in the last 24 months? | 6 | 2 | 3 | 3 | 2 | 0 | 0 | 1 |
| Number of $100M+ financings in the last 24 months? | 3 | 1 | 2 | 2 | 1 | 0 | 0 | 0 |
| Largest financing in the last 24 months? | $198M | $110M | $1,000M | $260M | $298M | $45M | $39.8M | $66M |
| Details for largest financing | BioAge IPO | Insilico Series E | Retro Bio Series A | Neko Health Series B | Function Health Series B | Cleara Series B | HLI Series B | Timeline Nutrition |
| Average financing size in the last 24 months? | ~$76M | ~$51M | ~$213M | ~$108M | ~$78M | ~$30M | ~$23M | ~$30M |
| Median financing size in the last 24 months? | ~$50M | ~$57M | ~$65M | ~$50M | ~$15M | ~$30M | ~$18M | ~$15M |
| Number of follow-on financings in the last 24 months? | 9 | 2 | 5 | 3 | 4 | 2 | 3 | 2 |
| Number of new funded startups in the last 24 months? | 3 | 3 | 2 | 2 | 1 | 2 | 0 | 0 |
| Number of academic spin-outs in the last 24 months? | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Estimated number of active VC-backed companies? | 50-70 | 20-30 | 15-20 | 25-40 | 20-30 | 12-18 | 15-25 | 30-50 |
| Number of disclosed shutdowns in the last 24 months? | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Details for shutdowns | Calico-AbbVie ended, Unity dissolved | - | Turn Bio collapsed | - | - | Unity dissolved | - | - |
| Number of clinical trials started in the last 24 months? | 4 | 3 | 3 | 1 | 0 | 2 | 0 | 0 |
| Number of human study results reported in the last 24 months? | 2 | 1 | 0 | 1 | 0 | 2 | 0 | 0 |
| Number of patents filed or granted in the last 24 months? | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 1 |
| Details for patents | Longeveron lifespan patent | Insilico, Recursion portfolios | - | - | Elysium, TruDiagnostic | - | - | NOVOS formulations |
| Number of new products or lead programs launched in the last 24 months? | 2 | 1 | 2 | 1 | 3 | 1 | 2 | 2 |
| Number of pharma partnerships in the last 24 months? | 3 | 3 | 2 | 1 | 0 | 0 | 1 | 0 |
| Number of strategic partnerships in the last 24 months? | 2 | 2 | 3 | 0 | 1 | 1 | 1 | 0 |
| Number of acquisitions in the last 24 months? | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Funding Activity Score | High | Medium | High | Medium | Medium | Low | Low | Low |
| Ecosystem Depth Score | High | Medium | Medium | Medium | Medium | Low | Low | Low |
| Validation Momentum Score | High | High | Medium | Low | Low | Medium | Low | Low |
| Strategic Validation Score | High | High | Medium | Low | Low | Low | Low | Low |
| Overall Investability Score | High | High | Medium | Medium | Medium | Low | Low | Low |
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Insights
We compared eight longevity market segments across 20 investability signals spanning funding activity, ecosystem depth, clinical validation, and strategic endorsement: age-related disease drugs, drug discovery platforms, cellular reprogramming, preventive health, biomarkers, senolytics, longevity clinics, and consumer products. Each segment was scored using publicly disclosed deals and events from April 2024 to April 2026. Here is what stood out.
- Three tech billionaires account for over $1.5 billion of the total longevity funding tracked here. Sam Altman put over $1.18 billion into Retro Biosciences, Brian Armstrong invested $110 million to co-found NewLimit, and Daniel Ek backed Neko Health with over $325 million. This market is driven by individual conviction about mortality, not by traditional venture capital patterns.
- Retro Biosciences' $1 billion Series A represents roughly 58% of all pure-play longevity funding raised in 2025. Remove that single deal, and the sector's year-over-year growth looks modest rather than explosive. The round was backed almost entirely by Sam Altman and a small group of tech investors.
- Follow-on financings outnumber new company fundings roughly 3 to 1 across all eight categories. Out of approximately 42 identified deals, only about 12 went to newly funded startups. Capital is concentrating in existing companies rather than seeding new scientific approaches.
- Cellular reprogramming absorbed over $1.2 billion in 24 months with zero Phase 2 human data. No reprogramming company has reported human safety, biomarker, or functional data yet. The capital deployed massively exceeds the clinical evidence base in that segment.
- Senolytics raised only $120 million across four deals in 24 months, with no single round exceeding $45 million. Unity Biotechnology's clinical failure and subsequent dissolution made the entire mechanism radioactive for generalist venture investors. Senescent cells are implicated in virtually every age-related disease, making this the most underfunded category relative to its scientific basis.
- Consumer longevity supplements attracted no significant new venture funding in 24 months, and zero newly funded startups emerged. Timeline Nutrition's $66 million round in January 2024 looks like a last-of-era deal. The surviving companies will likely become cash-flow businesses, not venture-scale outcomes.
- Longevity clinics raised only $68 million despite generating revenue from day one through memberships that can exceed $15,000 per year. Zero new clinic operators emerged with venture funding in this window. Venture investors want 100x returns, and service businesses scale linearly, creating a structural funding gap.
- The biomarker segment raised $390 million total, but Function Health accounts for $351 million of it. Strip out that single company, and the rest of the category raised only $39 million. True biomarker science like epigenetic clocks and proteomic aging signatures remains starved of commercial capital.
- Preventive health companies are reaching unicorn valuations with no drugs, clinical trials, or regulatory approvals. Neko Health reached a $1.8 billion valuation on $260 million raised, and Function Health reached $2.5 billion on $298 million raised. The market is pricing consumer engagement and revenue potential over clinical evidence.
- Eli Lilly invested across reprogramming, senolytics, AI drug discovery, and metabolic aging in the past 24 months. Its positions include NewLimit, Oisin Biotechnologies (via AbbVie Ventures), Insilico Medicine ($2.75 billion deal), and Fauna Bio. No other pharma company has built a comparable option portfolio on aging biology.
- Age-related disease drugs and drug discovery platforms both scored High on strategic validation. These two categories each attracted 3 pharma partnerships, 2 strategic partnerships, and 1 acquisition in the past 24 months. Insilico Medicine alone signed deals worth over $3.6 billion with Eli Lilly and Servier within three months.
- Every company that raised $50 million or more in this window prominently mentions AI or machine learning. The real differentiator is now proprietary data, not the AI label itself. Companies with unique datasets, like NewLimit's single-cell genomics or BioAge's human longitudinal cohorts, are pulling ahead.
- BioAge Labs is the sector's most important cautionary tale from the past 24 months. The company raised $170 million in its Series D, completed a $198 million IPO, and signed a Novartis deal worth up to $550 million. Then its lead drug azelaprag failed in Phase 2, and shares fell roughly 80%.
- Approximately 80 to 85% of longevity funding goes to US-based companies. The only notable exceptions in this window are Neko Health in Sweden, Insilico Medicine in Hong Kong, and Cleara Biotech in the Netherlands. Japan receives zero significant longevity startup funding despite having the world's oldest population.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Is longevity funding overly concentrated in a small number of segments or headline rounds?
Yes. Retro Biosciences' $1 billion Series A in January 2025 represented roughly 58% of all pure-play longevity therapeutic funding in the first half of that year. The reprogramming segment captured $1.28 billion over 24 months across 6 financings, but $1 billion came from one round for one company funded predominantly by one individual. Strip that round, and reprogramming drops from first to fourth.
The same pattern repeats elsewhere. In biomarkers, Function Health's $298 million accounts for 76% of the segment total. In preventive health, Neko Health's $260 million represents 48%. In consumer products, Timeline Nutrition's $66 million is 73%. The healthiest segment by distribution is age-related disease drugs: 11 financings, a $76 million average but $50 million median, and its largest round (BioAge's $198 million IPO) representing only 24% of the segment total.
Longevity Technology's DLT platform reported a sector-wide average deal size of $91.2 million versus a median of $21.8 million in Q1 2026. That 4.2x gap confirms extreme right-tail concentration. The typical longevity financing event remains a $20 to $25 million raise, not the headline rounds that dominate coverage.
Which longevity segments attracted the most capital over the last 24 months?
Ranked by total capital raised from April 2024 to April 2026: cellular reprogramming at approximately $1.28 billion (6 deals), age-related disease drugs at $835 million (11 deals), preventive health at $542 million (5 deals), biomarkers at $390 million (5 deals), discovery platforms at $255 million (5 deals), senolytics at $120 million (4 deals), consumer products at $91 million (3 deals), and longevity clinics at $68 million (3 deals).
The reprogramming ranking is almost entirely a Retro Biosciences artifact. Remove one deal and it drops to fourth. Quality of capital formation produces a different ranking. Age-related disease drugs lead on breadth with 11 deals, 3 newly funded startups, and 9 follow-on rounds. Discovery platforms rank second with 3 newly funded startups. Reprogramming ranks fifth on capital quality despite ranking first on volume.
The critical distinction: reprogramming looks dominant on capital totals but weak on capital quality. Discovery platforms appear modestly funded but have the strongest strategic validation. Insilico Medicine alone secured deals with Servier and Eli Lilly totaling over $3.6 billion in potential milestone value, which dwarfs the raw funding totals of several other segments combined.
Which longevity segments show broad-based momentum rather than dependence on a few standout companies?
Age-related disease drugs show the broadest momentum. Drug discovery platforms rank second. Every other segment depends heavily on one or two flagship companies for most of its capital and milestones.
Age-related disease drugs is the only segment with double-digit financings (11 in 24 months), 3 newly funded startups, and 9 follow-on rounds. No single company dominates: BioAge's $198 million IPO represented only 24% of the segment. The segment spans multiple mechanisms (NLRP3 inhibition, GDF11, mesenchymal stem cells, PAI-1 inhibition) across multiple indications. Drug discovery platforms produced 3 newly funded startups and the Recursion-Exscientia merger ($688 million) added structural scale.
Segments that appear broad but are actually concentrated: in preventive health, Neko ($260 million) and OURA ($200 million) together account for 85% of capital. In biomarkers, Function Health's $351 million dwarfs every other company combined. The sharpest test is new company formation. Age-related disease drugs and discovery platforms lead with 3 each. Longevity clinics and consumer products produced zero.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which longevity segment has recently crossed a critical threshold in ecosystem maturity, validation, or strategic relevance?
Drug discovery platforms applied to aging have crossed a critical threshold in strategic relevance. No other segment has accumulated comparable external validation from serious counterparties in this window.
Insilico Medicine secured an $888 million collaboration with Servier in January 2026 ($32 million upfront) and a $2.75 billion deal with Eli Lilly in March 2026 ($115 million upfront, exclusive worldwide licensing rights). Combined potential milestone value exceeds $5.7 billion. Recursion acquired Exscientia for $688 million in early 2025, creating the largest AI drug discovery entity by pipeline breadth.
The quality of counterparties matters. Eli Lilly is the world's most valuable pharma company. Servier is a top-15 global pharma by R&D spend. These are companies committing exclusive licensing rights, not speculative equity checks. By comparison, reprogramming has $1.28 billion in capital but zero pharma licensing deals. In early 2024, AI drug discovery applied to aging was a research proposition. By April 2026, the segment has moved from interesting technology to pharma procurement category.
Which longevity segments remain too fragile or too thinly populated to be truly investable?
Consumer longevity products, longevity clinics, and to a lesser extent senolytics. Two are structurally uninvestable from a venture perspective. The third is recovering from stigma.
Consumer products is effectively dead as a venture category: 3 deals in 24 months, zero newly funded startups, $91 million total, and no clinical trials, pharma partnerships, or acquisitions. Longevity clinics raised only $68 million, with zero new operators entering. The segment has real revenue (Fountain Life charges $15,000 or more per membership), but VCs require 100x return potential and service businesses scale linearly.
Senolytics is thinly funded ($120 million, 4 deals) and experienced the sector's highest-profile shutdown when Unity Biotechnology dissolved in September 2025. But it has recent positive indicators: Rubedo reported positive Phase 1 data in March 2026 across psoriasis, atopic dermatitis, and photoaged skin. Senolytics is underfunded because of stigma from Unity's failure, not because of weak science. The GPX4 ferroptosis mechanism that Rubedo pursues is mechanistically distinct from Unity's approach and avoids the tolerability issues that destroyed it.
Which longevity segment shows the strongest validation momentum today?
Drug discovery platforms. From April 2025 to April 2026, Insilico Medicine alone accumulated $3.6 billion in pharma deal value (Servier $888 million, Eli Lilly $2.75 billion), with $147 million in combined upfront payments. Insilico completed an HKEX IPO raising approximately $293 million in December 2025, the only longevity-adjacent company to access public markets in this window.
Age-related disease drugs produced smaller but notable validation: Longeveron published Phase 2b data in Cell Stem Cell, and BioAge maintained its Novartis partnership post-failure. Senolytics produced positive Phase 1 data (Rubedo, March 2026), but no pharma partnership followed. Reprogramming has high capital momentum but low validation momentum: $1.28 billion in funding produced one Phase 1 enrollment with no data yet.
The distinction between capital momentum and validation momentum is critical. Reprogramming has the most capital momentum. Discovery platforms have the most validation momentum. Investors who conflate the two will misprice both segments.
Which longevity segment shows the strongest strategic validation from pharma, partners, or acquirers?
Drug discovery platforms, by a wide margin. Within 24 months the segment accumulated over $4.4 billion in disclosed potential deal value: Insilico-Lilly at $2.75 billion ($115 million upfront), Insilico-Servier at $888 million ($32 million upfront), a prior Insilico-Lilly deal exceeding $100 million, the Recursion-Exscientia acquisition at $688 million, and ongoing Recursion collaborations with Roche, Genentech, and Bayer.
Age-related disease drugs have the BioAge-Novartis partnership ($530 million potential), which survived after BioAge's lead drug failed. Reprogramming has equity backing (NewLimit-Lilly) and an AI partnership (Retro-OpenAI), but no pharma has licensed a reprogramming therapeutic asset. Senolytics has zero disclosed pharma partnerships.
Eli Lilly has placed bets across age-related disease drugs, reprogramming, preventive health, and discovery platforms. No other pharma has this breadth. But its heaviest operational commitment is in discovery platforms: the Insilico-Lilly deal grants exclusive worldwide rights to develop, manufacture, and commercialize specific preclinical oral therapeutics.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which longevity segments are advancing scientifically faster than they are being funded?
Senolytics. It raised only $120 million across 4 deals in 24 months, less than BioAge's single IPO, less than Function Health's single Series B, and less than one-tenth of reprogramming's total. Yet it produced more clinical proof points per dollar deployed than any other segment.
Rubedo Life Sciences reported positive Phase 1 data in March 2026 for RLS-1496, the first GPX4 modulator to enter human trials, showing dose-dependent clinical signals across three skin conditions with histologic evidence of senescent cell clearance. A systemic formulation is planned for Phase 1 in 2026. Unity Biotechnology, despite dissolving in September 2025, released Phase 2b ASPIRE data showing biological activity in diabetic macular edema, proving the mechanism had merit even as the company failed.
The market is underpricing senolytics because of Unity's collapse. Unity failed on a BCL-xL inhibitor with tolerability issues. Rubedo's GPX4 mechanism is mechanistically distinct. The numbers: senolytics spent $120 million and generated 2 trial starts, 2 human readouts, and 1 FDA IND clearance. Reprogramming spent $1.28 billion and generated 1 enrollment with no data yet.
Which longevity segment appears most underfunded relative to its scientific promise?
Senolytics. It raised $120 million over 24 months while targeting a mechanism implicated in virtually every age-related disease, backed by genetic evidence showing approximately 25% lifespan extension in mouse models, and now supported by positive Phase 1 human data.
Senescent cell accumulation is one of the nine hallmarks of aging, causally implicated in cancer, atherosclerosis, osteoarthritis, pulmonary fibrosis, neurodegeneration, diabetes, and skin aging. Unlike reprogramming, which requires viral vectors or mRNA, senescent cell clearance can be achieved with conventional small molecules. This makes senolytics more druggable than reprogramming and more scalable than cell therapies.
The underfunding is explained by two correctable factors: Unity's failure creating category-wide investor PTSD, and the absence of a market framework investors can model. There is no ICD code for senescent cell accumulation. This is a narrative problem, not a scientific problem.
Which longevity segment appears most overcapitalized relative to its evidence base?
Cellular reprogramming. The segment has absorbed approximately $4.7 billion in cumulative funding (Altos Labs $3 billion, Retro approximately $1.18 billion, NewLimit approximately $275 million). What has $4.7 billion produced in human evidence as of April 2026? One Phase 1 enrollment (Retro, RTR242, December 2025, healthy volunteers). No readout, no Phase 2, no efficacy data of any kind.
Altos Labs ($3 billion) has zero clinical trials started and zero IND filings. Retro ($1.18 billion) dosed its first patient in December 2025, but the trial is for an autophagy compound, not a reprogramming therapy. NewLimit ($275 million) has not entered the clinic. The fundamental delivery problem remains unsolved: reprogramming requires viral vectors (carcinogenicity risk), LNP-mRNA (limited mostly to liver), or small molecules (low potency).
The comparison that clarifies: Insilico Medicine raised approximately $400 million and produced 20 preclinical candidates, 4 or more clinical-stage assets, and over $5.7 billion in pharma deal value. The reprogramming segment raised 10 times more and produced roughly 10 times less. Reprogramming may be appropriately funded on a 10-year horizon, but investors pricing it today are paying for 2030 optionality at 2026 valuations.
Which longevity segment shows the biggest mismatch between narrative momentum and underlying progress?
Cellular reprogramming. The segment dominates longevity coverage across every media tier: Retro's $1 billion raise and Sam Altman, Altos' $3 billion and Jeff Bezos, NewLimit and Brian Armstrong, the OpenAI-Retro partnership, Bryan Johnson's personal narrative. The segment has become the default media framing for longevity itself.
What has actually been delivered: zero efficacy data, one Phase 1 enrollment for an autophagy compound (not a reprogramming therapy), zero product launches, zero IND filings for any reprogramming therapy, zero pharma licensing deals, zero exits. The core promise of reprogramming tissues to a younger state has not been tested in a single human being.
Discovery platforms generated $5.7 billion in pharma deal value, an IPO, and multiple clinical-stage assets with a fraction of the coverage. Senolytics produced positive Phase 1 human data, Phase 2b biological activity, and an FDA IND clearance on $120 million total with almost no mainstream coverage. Reprogramming has roughly 10 times the media coverage of senolytics but one-tenth the clinical evidence. The risk is that a single clinical disappointment triggers a correction disproportionate to the setback, as BioAge's Phase 2 failure triggered an 80% stock crash.
This chart, featured in our longevity market deck, shows how wearable longevity devices have driven growth in the longevity market over time
This tracker is a live research tool we maintain to assess which longevity market segments appear most attractive for investment today. It is updated as new evidence emerges.
We use recent, publicly observable signals rather than theoretical judgments. All questions are framed over a 12-month or 24-month window to keep the comparison current and auditable. We assign High, Medium, or Low ratings so that High always indicates stronger segment attractiveness.
Funding Activity reflects capital inflow and financing strength. Ecosystem Depth reflects company formation, density, and resilience. Validation Momentum reflects tangible scientific, clinical, and product progress. Strategic Validation reflects external endorsement through partnerships and acquisitions. The Overall Investability Score is an aggregate judgment based on these four underlying scores.
These figures are compiled from publicly disclosed deals only. The actual numbers are likely higher, particularly for seed rounds and international deals that receive less English-language press coverage. Our figures cover only the pure-play longevity and aging-specific companies that clearly fit within these eight categories, excluding broader oncology, cardiology, or GLP-1 plays that are only tangentially aging-related. Some deals disclosed during this period span category boundaries. You can find more details and additional analysis in our longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Related blog posts
- The startups that have raised the most funding in the longevity market
- The most highly valued startups in the longevity market
- The full range of business models in the longevity market
- Who are the leading cellular reprogramming companies today?
- How strong is fundraising in the longevity market right now?
